Mode
Text Size
Log in / Sign up
Phase 4 N=40 Randomized Single-blind Supportive Care

Genicular Nerve Block for Total Knee Arthroplasty

Post-operative Pain

Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Nov 2020
Primary outcome: Primary: Opioid Consumption at 24 Hours Post-op — 22.9; 58.1 milligrams of oral morphine equivalents

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
15mL 0.25% bupivacaine (Drug); Genicular nerve block (Procedure); Saline (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Duke University
Primary completion
Oct 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Opioid Consumption at 24 Hours Post-op
22.9; 58.1
SECONDARY
Worst Pain Rating Score (NRS-11) at Rest on Postoperative Day 1
2.7; 3.5
SECONDARY
Worst Pain Rating Score (NRS-11) With Movement on Postoperative Day 1
4.9; 6.3
SECONDARY
Total Opioid Consumption Through 48 Hours
50.3; 97.6
SECONDARY
Opioid Consumption on Postoperative Day 7
10.4; 22.6
SECONDARY
Worst Pain Rating Score (NRS-11) on Postoperative Day 7
4.4; 5.0
SECONDARY
Sleep Quality Measured by Number of Times Awakened by Pain During the First Postoperative Night
0; 1
SECONDARY
Patient Satisfaction With Pain Control at 24 h
9.1; 8.6
SECONDARY
Patient Satisfaction With Pain Control on Postoperative Day 7
8.8; 8.9
SECONDARY
20 Meter Walk Test Time Performed on Postoperative Day 1
74.2; 80.2

Summary

This study seeks to examine the analgesic efficacy of genicular nerve blocks for pain after total knee replacement.

Eligibility Criteria

Inclusion Criteria

  • Subjects scheduled for primary elective total knee arthroplasty
  • American Society of Anesthesiologists Physical Status I-III
  • BMI 18-40 kg/m2

Exclusion Criteria

  • Inability to cooperate with protocol
  • Inability to understand or speak English
  • Allergy to ropivacaine, bupivacaine or other local anesthetic
  • Contraindication to peripheral nerve block (e.g. local infection, neurologic deficit or disorder, previous trauma or surgery to ipsilateral knee, etc.)
  • Revision knee surgery
  • Chronic opioid consumption (daily morphine equivalent of >30 mg for at least four weeks prior to surgery)
  • History of chronic pain
  • History of psychiatric disorder
  • History of diabetes mellitus
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03706313). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search